{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:56Z","timestamp":1761870476503,"version":"build-2065373602"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.clml.2011.12.004","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T21:38:31Z","timestamp":1327959511000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular Resistance: An Early Indicator for Treatment Change?"],"prefix":"10.1016","volume":"12","author":[{"given":"Carmen","family":"Fava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.12.004_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.clml.2011.12.004_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: implications for imatinib therapy","volume":"44","author":"Alvarez","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clml.2011.12.004_bib4","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.12.004_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.12.004_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.clml.2011.12.004_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.clml.2011.12.004_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.12.004_bib9","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2011.12.004_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.12.004_bib12","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.12.004_bib13","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib14","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","article-title":"Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2011.12.004_bib15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10428194.2010.546917","article-title":"New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia","volume":"52","author":"Fullmer","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.12.004_bib16","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","article-title":"Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","article-title":"Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib19","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.12.004_bib20","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"year":"2010","series-title":"Sprycel (dasatinib) tablets [prescribing information]","key":"10.1016\/j.clml.2011.12.004_bib21"},{"key":"10.1016\/j.clml.2011.12.004_bib22","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2007.0044","article-title":"Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors","volume":"5","author":"Radich","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2011.12.004_bib23","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib24","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib25","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.12.004_bib27","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib28","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2011.12.004_bib29","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib30","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1158\/1078-0432.CCR-07-1112","article-title":"A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response","volume":"13","author":"Press","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib31","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2008.18.6999","article-title":"Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response","volume":"27","author":"Kantarjian","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib32","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2011.12.004_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/sj.leu.2404893","article-title":"CD34+\/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate","volume":"22","author":"Bocchia","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.004_bib34","first-page":"162","article-title":"Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment","volume":"91","author":"Columbat","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.12.004_bib35","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.V112.11.2113.2113","article-title":"Long term follow up of patients with CML in chronic phase treated with first-line imatinib suggests that earlier achievement of a major molecular response leads to greater stability of response [abstract]","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.21055","article-title":"Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase","volume":"83","author":"Hess","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2011.12.004_bib38","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood.V114.22.859.859","article-title":"Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients [abstract]","volume":"114","author":"Mahon","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib39","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2011.12.004_bib40","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","article-title":"Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate","volume":"11","author":"Cortes","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib41","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1158\/1078-0432.CCR-05-2574","article-title":"Achieving a major molecular response at the time of a complete cytogenic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients","volume":"12","author":"Iacobucci","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-008-0548-y","article-title":"Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up","volume":"88","author":"Qin","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2011.12.004_bib43","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL levels at and after the time of a complete cytogenic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib44","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"issue":"suppl","key":"10.1016\/j.clml.2011.12.004_bib45","article-title":"Monitoring response to imatinib by quantitative real-time polymerase chain reaction (RQ-PCR) in chronic phase, chronic myeloid leukemia patients in complete cytogenetic remission [abstract]","volume":"26","author":"Pavlovsky","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-08-1195","article-title":"Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response","volume":"15","author":"Palandri","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib47","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.004_bib48","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2011.12.004_bib49","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progressions among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose therapy","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib50","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.004_bib51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2011.12.004_bib52","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib53","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib54","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib55","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"226","author":"Shah","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib56","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression","volume":"29","author":"Khorashad","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1182\/blood.V116.21.889.889","article-title":"A review of mutation analysis in the TOPS trial of standard dose versus high dose IM in CML suggests that refinements to the ELN recommendations for mutation screening may be appropriate [abstract]","volume":"116","author":"Branford","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib58","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib59","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcome of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib61","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.3324\/haematol.11369","article-title":"Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation","volume":"92","author":"Nicolini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.12.004_bib62","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib63","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib64","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib65","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.004_bib66","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2011.12.004_bib67","first-page":"337","article-title":"The P-loop mutations Y235H and E255K\/V may develop more frequently than T315I during nilotinib therapy after imatinib failure and are associated with progression in patients with Ph-positive leukemia [abstract]","volume":"92","author":"Branford","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.12.004_bib68","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib69","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib70","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib71","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance to intolerance to imatinib: interim results of a phase II study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib72","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2011.12.004_bib73","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib74","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib75","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","article-title":"Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels","volume":"33","author":"Forrest","year":"2009","journal-title":"Leukemia Res"},{"key":"10.1016\/j.clml.2011.12.004_bib76","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/leu.2009.32","article-title":"Imatinib dose escalation for chronic phase-chronic myelogenous leukemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy","volume":"23","author":"Rea","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2011.12.004_bib77","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood.V110.11.2967.2967","article-title":"Efficacy of imatinib mesylate dose-escalation in CML patients showing suboptimal response to standard dose [abstract]","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib78","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood.V110.11.1035.1035","article-title":"Impact of imatinib mesylate dose escalation on resistance and sub-optimal responses to standard-dose therapy in patients (pts) with chronic myeloid leukemia (CML) [abstract]","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.1016\/j.clml.2011.12.004_bib79","article-title":"Dose escalation of imatinib in CML patients with sub-optimal response to conventional dosage: is it worth it? [abstract]","volume":"26","author":"Batra","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib80","first-page":"705","article-title":"Real-world adherence rates of chronic myeloid leukemia patients to higher doses of imatinib","volume":"13","author":"Sun","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clml.2011.12.004_bib81","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1182\/blood.V114.22.2201.2201","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib82","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood.V114.22.2206.2206","article-title":"Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib [abstract]","volume":"114","author":"Yang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib83","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib84","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib85","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.12.004_bib86","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib87","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib88","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2011.12.004_bib89","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.12.004_bib90","doi-asserted-by":"crossref","first-page":"25a","DOI":"10.1182\/blood.V110.11.25.25","article-title":"IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]","volume":"110","author":"Hochhaus","year":"2007","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011006100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:55Z","timestamp":1761870175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011006100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S2152265011006100"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Resistance: An Early Indicator for Treatment Change?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}